2026 ACC/AHA Dyslipidemia Guideline: What the Evidence Shows
A comparative evidence synthesis of the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline versus the 2025 ESC/EAS Focused Update — risk assessment, LDL-C goals, Lp(a) screening, and emerging therapies in primary and secondary prevention.
This is an original evidence synthesis drawing on the full 2026 guideline document, the 2025 ESC/EAS Focused Update, and the major randomized trials that informed both. See References for source studies.
One-Minute Takeaway
One-Minute Takeaway
- The 2026 ACC/AHA Dyslipidemia Guideline restores explicit LDL-C treatment goals (<55 mg/dL for very-high-risk ASCVD, <70 mg/dL for ASCVD not at very high risk, <100 mg/dL for borderline/intermediate primary prevention), replacing the threshold-only approach of 2018.
- PREVENT-ASCVD equations replace the Pooled Cohort Equations for adults aged 30–79, providing both 10- and 30-year risk estimates; the older equations were shown to overestimate 10-year risk by approximately 40–50% in contemporary cohorts.
- Universal Lp(a) measurement at least once in adulthood is now a Class I recommendation, bringing US practice in line with the 2019 ESC/EAS and 2021 Canadian positions.
- Bempedoic acid (CLEAR Outcomes), evolocumab primary prevention (VESALIUS-CV), and inclisiran broaden the nonstatin armamentarium, though the 2026 document was finalised before VESALIUS-CV and may be outpaced on primary-prevention PCSK9 use.
- The 2026 ACC/AHA and 2025 ESC/EAS documents remain largely concordant on LDL-C targets but diverge on risk calculators (PREVENT vs SCORE2), ACS-hospitalisation combination therapy, and the level of detail on Lp(a) thresholds.
Why This Topic Matters
Atherosclerotic cardiovascular disease remains the leading cause of death globally, and approximately one in four US adults carries an LDL-C level that elevates their risk of myocardial infarction and stroke. The 2018 AHA/ACC cholesterol guideline reshaped US practice around statin intensity and fixed LDL-C thresholds for nonstatin add-on therapy, but it arrived before a decade of evidence reshaped the field — from lifelong exposure data, to contemporary risk calibration, to outcome trials of three new drug classes.
The 2026 guideline, now co-signed by eleven societies including the ACC, AHA, ADA, and NLA, retitles the document from “Blood Cholesterol” to “Dyslipidemia” to reflect the broadened focus on triglyceride-rich remnants, apolipoprotein B, and lipoprotein(a) — atherogenic particles that contribute to residual risk even at target LDL-C. The parallel 2025 ESC/EAS Focused Update makes similar structural changes using SCORE2/SCORE2-OP, allowing for direct transatlantic comparison for the first time since both bodies updated within a twelve-month window.
What Evidence Was Reviewed
This synthesis draws on the full text of the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline, the 2025 ESC/EAS Focused Update, and the pivotal randomized outcome trials and risk-equation derivation studies that populated both evidence bases. Where the guideline documents themselves cite meta-analyses (notably CTTC pooled analyses of LDL-C lowering and CV outcomes), those remain the anchor for certainty grading. The trials below were chosen because each changed — or is currently changing — at least one specific guideline recommendation.
| Study | Design | n | Population | Key Finding | Quality |
|---|---|---|---|---|---|
| Blumenthal et al. 2026 | Clinical practice guideline | NR | Adults and children with dyslipidemia | 11-society consensus; introduces PREVENT, restores LDL-C goals, universal Lp(a) | Guideline |
| Mach et al. 2025 (ESC/EAS Update) | Focused guideline update | NR | European adult population | Retains 2019 LDL-C targets; adopts SCORE2/SCORE2-OP; upgrades bempedoic acid | Guideline |
| Khan et al. 2023 (PREVENT derivation) | Prospective cohort pooling | 6,612,004 | Diverse US adults 30–79 | Race-free equations; improved discrimination over PCE; 10- and 30-year horizons | Moderate–High |
| Bohula et al. 2025 (VESALIUS-CV) | RCT, double-blind, placebo-controlled | 12,257 | High-risk adults without prior MI or stroke | Evolocumab reduced 3-point MACE by 25% (HR 0.75, 95% CI 0.65–0.86) | High |
| Nissen et al. 2023 (CLEAR Outcomes) | RCT, double-blind, placebo-controlled | 13,970 | Statin-intolerant adults, primary + secondary prevention | Bempedoic acid reduced 4-point MACE; effect consistent in diabetes subgroup | High |
| Sabatine et al. 2017 (FOURIER) | RCT, double-blind, placebo-controlled | 27,564 | Established ASCVD on statin | Evolocumab reduced MACE by 15% (HR 0.85, 95% CI 0.79–0.92); median follow-up 2.2 years | High |
| Schwartz et al. 2018 (ODYSSEY OUTCOMES) | RCT, double-blind, placebo-controlled | 18,924 | Recent ACS on maximally tolerated statin | Alirocumab reduced MACE by 15% (HR 0.85, 95% CI 0.78–0.93); all-cause mortality benefit | High |
| Ray et al. 2020 (ORION-10/11) | RCT, double-blind, placebo-controlled | 3,178 | ASCVD or equivalent on statin | Inclisiran (biannual siRNA) reduced LDL-C ~50%; CV outcome data pending (ORION-4, VICTORION-2P) | Moderate (lipid outcome) |
| CTT Collaboration 2019 pooled analysis | Meta-analysis of statin RCTs | ~170,000 | Broad CV risk spectrum | Each 39 mg/dL LDL-C reduction → ~22% relative reduction in major vascular events | High |
| Bhatia 2025 (Lp(a) universal screening review) | Narrative review / position paper | NR | Adults across risk categories | High yield of single test; >90% genetically determined; supports once-lifetime screening | Low (narrative) |
Key Findings: What the 2026 Guideline Changes
Theme 1 — Risk assessment moves from PCE to PREVENT, and from 10 years to 30 years
The single most far-reaching change is the replacement of the 2013 Pooled Cohort Equations with the PREVENT-ASCVD equations for primary-prevention risk estimation in adults aged 30–79 with LDL-C 70–189 mg/dL. PREVENT was derived from a pooled dataset of more than 6.5 million diverse US adults, is race-free, incorporates kidney and metabolic health factors, and — crucially — provides both 10-year and 30-year risk estimates. Because the older PCE consistently overestimated 10-year risk in contemporary cohorts by 40–50%, PREVENT will reclassify a substantial fraction of patients downward on 10-year risk while elevating the visibility of younger adults whose 30-year (but not 10-year) risk is high. The ESC/EAS 2025 Focused Update takes a parallel but distinct step by adopting SCORE2 and SCORE2-OP, which also broaden age range and incorporate non-fatal events but retain a 10-year-only horizon.
Clinical pearl. PREVENT’s 30-year risk output is the feature most likely to change conversations. A 35-year-old with LDL-C 160 mg/dL may have a 10-year ASCVD risk of only 2% yet a 30-year risk exceeding 20% — a framing that supports earlier lifestyle intervention and, in selected patients, earlier pharmacotherapy without relying on “risk-enhancer” exceptions.
Theme 2 — LDL-C goals are back, and they are lower than many clinicians were using
The 2018 ACC/AHA document deliberately avoided numeric LDL-C targets and instead used a threshold (<70 mg/dL) for triggering nonstatin add-on in very-high-risk ASCVD. The 2026 guideline returns to explicit goals: LDL-C <55 mg/dL (non-HDL-C <85 mg/dL) in very-high-risk clinical ASCVD, <70 mg/dL in ASCVD not at very high risk, and <100 mg/dL in borderline- or intermediate-risk primary prevention. These values align closely with the 2019 ESC/EAS and 2025 Focused Update targets, ending nearly a decade of transatlantic divergence on whether to name a goal at all. Supporting this shift is a linear relationship between achieved LDL-C and event reduction across the full range studied, with approximately 22% relative risk reduction per 39 mg/dL lowering (CTTC pooled analysis).
Theme 3 — Lp(a) moves from optional risk enhancer to universal Class I screening
Where the 2018 guideline listed Lp(a) as one of several “risk enhancers” without a specific testing trigger, the 2026 document recommends measuring Lp(a) at least once in every adult (Class I). This change reflects converging evidence that Lp(a) is more than 90% genetically determined, stable enough for single-test risk stratification, and causally linked to ASCVD and calcific aortic valve disease. No FDA-approved Lp(a)-specific therapy yet exists, but identifying elevated Lp(a) intensifies LDL-C targets, justifies earlier family screening, and prepares patients for emerging Lp(a)-lowering agents (olpasiran, pelacarsen) as outcome trials read out. The ESC/EAS 2025 update similarly endorses once-lifetime testing, with particular attention to levels ≥180 mg/dL that confer risk comparable to heterozygous FH.
Theme 4 — The nonstatin armamentarium has expanded and stratified
Five lipid-lowering agents have received FDA approval since the 2018 guideline — inclisiran, bempedoic acid, evinacumab, pelacarsen (under review), and most recently expanded indications for evolocumab in primary prevention. The 2026 guideline positions these therapies as add-ons to maximally tolerated statin (or in place of statin for intolerant patients) when LDL-C goals are not met, mirroring the stepwise structure of the 2022 ACC Expert Consensus Decision Pathway but now under formal guideline recommendation. Effect sizes cluster predictably: ezetimibe and bempedoic acid deliver roughly 18–25% additional LDL-C reduction; PCSK9 monoclonal antibodies and inclisiran deliver 50–60%. In CLEAR Outcomes, the primary-prevention subgroup showed a 30% reduction in 4-point MACE with a number needed to treat of 43 — a notable effect size for a population in which only one major primary-prevention outcome trial of a nonstatin had previously read out.
Theme 5 — VESALIUS-CV arrived just late enough to blur the new goals
The 2026 document had a December 2024 literature cutoff and was finalised before VESALIUS-CV was presented at AHA 2025. That trial randomised 12,257 high-risk adults without prior MI or stroke — two-thirds with subclinical atherosclerosis, one-third with high-risk diabetes — to evolocumab or placebo on top of optimised LDL-C lowering. Over 4.6 years, the PCSK9 monoclonal antibody reduced 3-point MACE by 25% (HR 0.75, 95% CI 0.65–0.86), 4-point MACE by 19% (HR 0.81, 95% CI 0.73–0.89), and showed a nominal 20% reduction in all-cause death, achieving an on-treatment LDL-C of approximately 45 mg/dL. Guideline authors have already written that future revisions should collapse the distinction between ASCVD “at very high risk” and “not at very high risk” and target <55 mg/dL for all ASCVD patients — a harmonisation that would make the US and European goals functionally identical.
Theme 6 — Subgroup and lifecycle considerations
The 2026 guideline endorses universal pediatric lipid screening between ages 9 and 11 — a significant strengthening over 2018’s selective screening position. Earlier testing (age 2 and above) is supported when there is a first-degree relative with premature ASCVD, severe hypercholesterolemia, or confirmed FH. For children with heterozygous FH, statin initiation from age 8–10 is explicitly supported; evolocumab is approved from age 10 and alirocumab from age 8. The rationale is straightforward: time-averaged LDL-C exposure from childhood onward is a stronger predictor of lifetime event risk than any single adult measurement, and starting a 33% LDL-C reduction at age 40 reduces cumulative exposure more than starting a 50% reduction at age 55. Young adults (under 40) with LDL-C ≥160 mg/dL or a strong family history of premature ASCVD are flagged for health-behaviour counselling and earlier pharmacotherapy consideration even when PREVENT 10-year risk is low — precisely the population PREVENT’s 30-year horizon illuminates.
Diabetes remains a high-risk designation warranting moderate- to high-intensity statin therapy for most patients aged 40–75, but the 2026 guideline narrows language around “diabetes automatically equals high-risk ASCVD” and instead directs clinicians to PREVENT for stratification and to biomarkers (including LDL-C, non-HDL-C, and apoB) for goal-setting. Importantly, the VESALIUS-CV diabetes subgroup — roughly half the trial population — showed consistent benefit from evolocumab, and the CLEAR Outcomes diabetes subgroup showed an absolute 2.4% MACE reduction with bempedoic acid over 3.4 years. Guideline authors have written that future updates should explicitly recommend more intensive LDL-C lowering in high-risk diabetes with at least one additional risk feature, reflecting emerging consensus that the old LDL-C <70 mg/dL target for this group may no longer be adequate.
Reported statin-associated muscle symptoms affect 7–29% of patients in observational studies, though much of this burden reflects the nocebo effect. The 2026 guideline maintains the stepped approach to statin rechallenge (lower dose, alternate agent, every-other-day dosing) but — for the first time in a US guideline — formally positions bempedoic acid as an evidence-based option for patients who remain unable to tolerate any statin dose. CLEAR Outcomes enrolled a population with mean baseline LDL-C 139 mg/dL, 30% primary prevention, 48% women, and achieved a 21.1% LDL-C reduction and statistically significant MACE reduction over 40 months. The drug’s hepatic-selective activation explains its muscle tolerability, and it does not raise HbA1c. The ESC/EAS 2025 update upgrades bempedoic acid to a Class I recommendation in the same population — one of few areas where the European document moves further than the US document.
The retitling of the document from “Blood Cholesterol” to “Dyslipidemia” foregrounds triglyceride-rich remnant lipoproteins as atherogenic particles beyond LDL. For persistently elevated triglycerides, statin therapy remains the foundation of pharmacotherapy as an adjunct to lifestyle intervention to reduce ASCVD risk. Dedicated triglyceride-lowering therapy is reserved for pancreatitis prevention in severe hypertriglyceridemia (TG ≥1000 mg/dL), where fibrates, omega-3 fatty acids, and — in familial chylomicronemia syndrome — volanesorsen are considered. Icosapent ethyl remains positioned for patients with residual ASCVD risk on statin therapy with TG 135–499 mg/dL based on REDUCE-IT, though the evidence has been tempered since 2018 by concerns raised by the STRENGTH trial about the mineral oil placebo.
The CPR framework — Calculate, Personalise, Reclassify and Reassess — positions CAC scoring as a selective reclassification tool for borderline- or intermediate-risk adults (men ≥40, women ≥45) in whom the benefit of statin therapy is uncertain. A CAC of zero in this population supports deferral with close follow-up; a CAC ≥100 (or the 75th percentile for age/sex) reclassifies upward toward statin therapy. Opportunistic detection of coronary calcium on non-cardiac chest CT is now explicitly recognised as a practical risk-assessment adjunct. The European approach retains greater flexibility, allowing CAC or carotid/femoral plaque assessment at the clinician’s discretion for moderate-risk individuals.
Quality and Consistency of Evidence
The 2026 guideline’s headline recommendations rest on differing evidence bases. Some — the LDL-C–lowering benefit of statins, the secondary-prevention benefit of PCSK9 monoclonal antibodies — are anchored in large meta-analyses of concordant RCTs. Others — universal Lp(a) screening and the choice of PREVENT over PCE — rely on derivation-and-validation studies, genetic analyses, and expert synthesis rather than outcome RCTs of the screening strategy itself. The summary below reflects this asymmetry.
What the Evidence Does Not Show
Specific areas where the 2026 ACC/AHA Dyslipidemia Guideline rests on inference rather than direct outcome evidence, or where the evidence arrived after the document’s literature cutoff.
- No outcome RCT of PREVENT-guided versus PCE-guided management. Adoption is justified by better calibration and discrimination in contemporary cohorts, but whether reclassifying patients changes event rates has not been tested.
- Lp(a) testing currently lacks an approved Lp(a)-specific therapy. Olpasiran (OCEAN(a)-Outcomes, expected 2026) and pelacarsen (HORIZON, expected 2025–2026) have not yet demonstrated ASCVD event reduction; identified high-Lp(a) patients must currently be managed by intensifying LDL-C lowering.
- Inclisiran’s cardiovascular outcome profile is pending. Its Class I positioning depends on RNA-interference pharmacology achieving PCSK9-monoclonal-antibody-equivalent LDL-C reduction; whether event reduction follows awaits ORION-4 and VICTORION-2P.
- VESALIUS-CV post-dates the guideline. The primary-prevention role of PCSK9 inhibitors in high-risk diabetes without atherosclerosis is supported by a single large RCT that the 2026 document could not formally incorporate; the first major update after this trial is still pending.
- Advanced lipoprotein testing beyond LDL-C, non-HDL-C, apoB, and Lp(a) has not been shown to improve outcomes. Advanced lipoprotein panels should be limited to scenarios where the additional information is likely to meaningfully change management.
- Pediatric long-term safety of early statin initiation is supported by observational cohorts up to two decades but lacks data beyond that horizon — a gap that matters for patients starting therapy at age 8–10.
- Treatment of isolated low HDL-C has no evidence-based pharmacotherapy; the 2026 guideline reflects this by removing any drug-therapy recommendation for low HDL-C as a standalone target.
Practical Implications for Clinical Practice
Based on the current evidence summarised in the 2026 guideline — and anticipating the VESALIUS-CV-driven adjustments likely in the next revision — the following considerations follow. These are framed as evidence-based options for clinician-patient decisions, not as directive recommendations.
Both documents converge on LDL-C targets but differ on implementation. The ESC/EAS 2025 update emphasises early, upfront combination therapy during the ACS index hospitalisation — high-intensity statin plus ezetimibe from admission in lipid-lowering-naive ACS patients expected to miss goal on statin alone (Class I). The 2026 ACC/AHA document retains a more stepped approach, with nonstatin add-on triggered after outpatient reassessment. Clinicians caring for post-ACS patients in US practice may reasonably consider the European upfront-combination strategy as an evidence-based alternative for patients with baseline LDL-C well above goal.
Evidence Grade and Bottom Line
Overall Evidence Grade: Strong (for LDL-C lowering and statin/PCSK9 inhibitor use); Moderate (for PREVENT adoption, bempedoic acid, and universal Lp(a) screening). The 2026 ACC/AHA guideline’s core recommendations on LDL-C lowering rest on decades of concordant RCTs and meta-analyses. Its newer structural elements — the PREVENT equations and universal Lp(a) screening — are supported by strong mechanistic and observational data but have not been tested as management strategies in outcome RCTs. The VESALIUS-CV trial, published after the guideline’s literature cutoff, strengthens the case for intensive LDL-C lowering across the ASCVD continuum and is likely to drive the next revision.
Strong-grade recommendations — particularly LDL-C targets and statin intensity — are unlikely to change substantially in the next revision. Moderate-grade recommendations (PREVENT adoption, bempedoic acid positioning, universal Lp(a) screening) may be refined as outcome data from OCEAN(a)-Outcomes, HORIZON, ORION-4, and VICTORION-2P read out between 2026 and 2028. Clinicians adopting the guideline today should plan for updates rather than delay implementation.
- Use PREVENT-ASCVD for primary-prevention risk estimation in adults aged 30–79; the 30-year risk output is especially valuable in younger patients.
- Apply explicit LDL-C goals — <55 mg/dL (very-high-risk ASCVD), <70 mg/dL (ASCVD not at very high risk), <100 mg/dL (borderline/intermediate primary prevention) — alongside percent-reduction thresholds.
- Measure Lp(a) at least once in every adult; the single test identifies a meaningful subset with elevated lifelong risk and informs family screening.
- Bempedoic acid, ezetimibe, PCSK9 inhibitors, and inclisiran expand nonstatin options for patients who do not reach goal on maximally tolerated statin.
- Limitation to keep in mind: the guideline’s literature cutoff (December 2024) pre-dates VESALIUS-CV and several ongoing Lp(a)-therapy outcome trials; expect refinements as that evidence matures.
Article Information
For Educational Purposes Only. This is an original evidence synthesis informed by the studies listed below. It does not replace clinical judgement. Drug dosages should be verified against current prescribing information.
References
- Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026. DOI: 10.1016/j.jacc.2025.11.016
- Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis. 2025;409:120479. DOI: 10.1016/j.atherosclerosis.2025.120479
- Bohula EA, Marston NA, Bhatia AK, et al. Evolocumab in patients without a previous myocardial infarction or stroke (VESALIUS-CV). N Engl J Med. 2025. DOI: 10.1056/NEJMoa2509648
- Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients (CLEAR Outcomes). N Engl J Med. 2023;388:1353–1364. DOI: 10.1056/NEJMoa2215024
- Khan SS, Matsushita K, Sang Y, et al. Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations. Circulation. 2023;149:430–449. DOI: 10.1161/CIRCULATIONAHA.123.067626
- Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). N Engl J Med. 2017;376:1713–1722. DOI: 10.1056/NEJMoa1615664
- Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (ODYSSEY OUTCOMES). N Engl J Med. 2018;379:2097–2107. DOI: 10.1056/NEJMoa1801174
- Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (ORION-10 and ORION-11). N Engl J Med. 2020;382:1507–1519. DOI: 10.1056/NEJMoa1912387
- Ray KK, Nicholls SJ, Li N, et al. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of CLEAR Outcomes. Lancet Diabetes Endocrinol. 2024;12:19–28. DOI: 10.1016/S2213-8587(23)00316-9
- Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. DOI: 10.1016/S0140-6736(10)61350-5
- Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering. J Am Coll Cardiol. 2022;80:1366–1418. DOI: 10.1016/j.jacc.2022.07.006
- Bhatia HS. Lipoprotein(a) at a “Tipping Point”: case to move to universal screening. Am J Prev Cardiol. 2025;23:101274. DOI: 10.1016/j.ajpc.2025.101274
- Shahu A, Feldman DI, Michos ED. 2018 AHA/ACC Multisociety Cholesterol Guideline vs 2019 ESC/EAS Dyslipidemia Guidelines: A Comparative Analysis. Medscape Cardiology. 2021. URL: medscape.com/viewarticle/952765
- Shahu A, Okunrintemi V, Tibuakuu M, et al. Comparison of Transatlantic Approaches to Lipid Management: The AHA/ACC/Multisociety Guidelines vs the ESC/EAS Guidelines. Mayo Clin Proc. 2020;95:998–1014. DOI: 10.1016/j.mayocp.2020.01.011
- Blumenthal RS, Morris PB, Michos ED, Ndumele CE. The 2026 Dyslipidemia Guideline: Editorial Perspective on a Continuous Work in Progress. J Am Coll Cardiol. 2026. URL: acc.org — 2026 Guideline Editorial